Letter to the Editor: A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Healthcare System

The letter to the editor discusses the challenges faced by patients with alopecia areata (AA) in the Military Healthcare System (MHS) due to the lack of access to JAK inhibitors like baricitinib and ritlecitinib, which are effective in treating severe refractory AA. Current TRICARE policies restrict treatments aimed at hair regrowth, impacting the quality of life for military personnel and veterans. The authors present two patient cases to highlight the issue and advocate for policy changes to allow these medications within the MHS, suggesting a case-by-case approach for active duty members. They emphasize the need for access to these treatments, noting that while JAK inhibitors have black box warnings, their risk profile is comparable to placebos, though long-term safety data is still needed.